Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print December 28, 2005, doi:10.1212/01.wnl.0000195887.63124.dc)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow CME: Take the course for this article:
 Volume 66, Number 3, February 14, 2006
Right arrow Data Supplement
Right arrow All Versions of this Article:
01.wnl.0000195887.63124.dcv1
66/3/436    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Góngora-Rivera, F.
Right arrow Articles by Santos-Zambrano, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Góngora-Rivera, F.
Right arrow Articles by Santos-Zambrano, J.
Received May 16, 2005
Accepted October 27, 2005

Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis

F. Góngora-Rivera MD, J. L. Soto-Hernández MD*, D. González Esquivel MS, H. J. Cook PhD, C. Márquez-Caraveo MD, R. Hernández Dávila MD, and J. Santos-Zambrano MD

From the Department of Neurology (F.R-G., C.M.-C., R.H.D., J.S.-Z.), Department of Infectious Diseases (J.L.S.-H.), and Neuropharmacology Laboratory (D.G.E., H.J.C.), Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.


* To whom correspondence should be addressed. E-mail: joseluis_sotohernandez{at}yahoo.com.

Abstract-- Thirty-six patients with subarachnoid and intraventricular cysticercosis were randomly assigned to receive albendazole at 15 or 30 mg/kg/day plus dexamethasone for 8 days. Results favored a higher dose, with larger cyst reduction on MRI at 90 and 180 days and higher albendazole sulfoxide levels in plasma. An albendazole course at 30 mg/kg/day combined with corticosteroids is safe and more effective than the usual dose. A single treatment was insufficient in intraventricular and giant cysts.




This article has been cited by other articles:


Home page
 NeurologyHome page
F. Gongora-Rivera, J. Luis Soto-Hernandez, P. Guevara, and J. Sotelo-Morales
IN NEUROCYSTICERCOSIS, CSF CYTOKINES CORRELATE WITH CEREBRAL BLOOD FLOW VELOCITIES
Neurology, September 30, 2008; 71(14): 1119 - 1122.
[Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A Fleury, M Hernandez, M Avila, G Cardenas, R J Bobes, M Huerta, G Fragoso, L Uribe-Campero, L J S Harrison, R M E Parkhouse, et al.
Detection of HP10 antigen in serum for diagnosis and follow-up of subarachnoidal and intraventricular human neurocysticercosis
J. Neurol. Neurosurg. Psychiatry, September 1, 2007; 78(9): 970 - 974.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by AAN Enterprises, Inc.